Proof of Concept Study of OC000459 in Eosinophilic Esophagitis
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This will be a randomised, double blind, placebo controlled, parallel group evaluation of the
effect of OC000459 given orally for eight weeks on active eosinophilic esophagitis.